SCHEMBL5813285

SCHEMBL5813285

CC(=O)C(N)CCC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.65
GRM8 O00222 1/20 0.65
GRM6 O15303 1/20 0.65
GRIN2D O15399 1/20 0.65
GRIN3B O60391 1/20 0.65
GSR P00390 1/20 0.65
GRIK1 P39086 1/20 0.65
GRM5 P41594 1/20 0.65
GRIA1 P42261 1/20 0.65
GRIA2 P42262 1/20 0.65
GRIA3 P42263 1/20 0.65
SLC1A3 P43003 1/20 0.65
SLC1A2 P43004 1/20 0.65
SLC1A1 P43005 1/20 0.65
GRIA4 P48058 1/20 0.65
GRIN1 Q05586 1/20 0.65
GRIN2A Q12879 1/20 0.65
GRIK2 Q13002 1/20 0.65
GRIK3 Q13003 1/20 0.65
GRIN2B Q13224 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755484 1.00 CYP1A2 (0.65) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL17830393 1.00 CYP1A2 (0.65) CYP1A2GRM8GRM6GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL4936629 0.98 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL23897855 0.86 ENPEP (0.52) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL27675061 0.86 ENPEP (0.52) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL11795885 0.84 ALDH1A1 (0.55) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL15797537 0.83 GRM8 (0.86) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL184512 0.83 GRM8 (0.86) CYP1A2GRM8GRM6GRIN2DGRIN3B
Glutamic Acid SCHEMBL2803034 0.83 GRM8 (0.86) CYP1A2GRM8GRM6GRIN2DGRIN3B
Glutamic Acid SCHEMBL184513 0.83 GRM8 (0.86) CYP1A2GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114965800-A Renal clear cell carcinoma biomarker and application thereof in early screening 山西医科大学 2022-08-30 CN claimed
CN-111406216-A Compounds, reagents and uses thereof 麦特博隆股份有限公司 2020-07-10 CN claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 WO claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
EP-3983020-B1 AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO TAGWORKS PHARMACEUTICALS B V (NL) 2024-06-26 EP disclosed
WO-2024080872-A1 STRAINED BICYCLONONENES TAGWORKS PHARMACEUTICALS B.V. (NL) 2024-04-18 WO disclosed
EP-3788032-B1 COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY TAGWORKS PHARMACEUTICALS B V (NL) 2024-01-24 EP disclosed
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES MIHKAL GMBH (CH) 2023-10-12 US disclosed
WO-2023158305-A1 MASKED IL12 PROTEIN TAGWORKS PHARMACEUTICALS B.V. (NL) 2023-08-24 WO disclosed
EP-3481383-B1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME CELLIX BIO PRIVATE LTD (IN) 2023-06-14 EP disclosed
WO-2023094679-A1 PHOTODYNAMIC THERAPY AND DIAGNOSIS RMW CHO GROUP LIMITED (CN) 2023-06-01 WO disclosed
WO-2023094680-A1 PHOTODYNAMIC THERAPY AND DIAGNOSIS RMW CHO GROUP LIMITED (CN) 2023-06-01 WO disclosed
US-7592368-B2 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-09-22 US disclosed
US-20080124274-A1 Compositions and methods for detecting and treating tumors containing acidic areas SUMMERTON JAMES EDWARD 2008-05-29 US disclosed
US-20070286803-A1 Compositions and methods for detecting and treating tumors containing acidic areas SUMMERTON JAMES EDWARD 2007-12-13 US disclosed
US-20070231256-A1 Compositions and methods for detecting and treating tumors containing acidic areas SUMMERTON JAMES E 2007-10-04 US disclosed
US-7244765-B2 Guanylhydrazone salts, compositions, processes of making and methods of using CYTOKINE PHARMASCIENCES, INC (US) 2007-07-17 US disclosed
WO-2006119283-A2 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J (US) 2006-11-09 WO disclosed
CN-1284086-A Conjugates useful in treatment of prostate cancer MERCK & CO INC (US) 2001-02-14 CN disclosed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES HTR2A, HTR2C, HTR1D CYP1A2 267/4885GRM8 345/4885GRM6 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.